Collate Valuation, Funding & Investors

Collate is valued at $1B as of June 2026.

Last Collate valuation

$1B

Undisclosed stage · Jun 2026

Last Collate funding round

$95M

Undisclosed stage · Jun 2026

Cumulative funding Collate raised

$125M

across 2 funding rounds

Key investors in Collate

  • Redpoint
  • Y Combinator
  • First Round Capital
  • Conviction Embed

Collate Overview

About Collate

Collate is a San Francisco-based platform leveraging artificial intelligence to automate documentation for drug development, medical devices, and diagnostics firms. It generates regulatory submissions, clinical protocols, and quality management documents from concept through commercialization, reducing preparation time by integrating with tools like Veeva and MasterControl. Serving life sciences companies worldwide, Collate ensures compliance with FDA, EMA, and ISO standards while streamlining collaborative authoring. Launched in 2022, the platform processes thousands of documents annually for biotech and medtech innovators.


Founded

2025

HQ

United StatesSan Francisco, CA

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Valuation

$1B (Jun 2026)

Collate Valuation

Collate is currently valued at $1B, based on its undisclosed-stage round in June 2026.

The $95M round was led by Redpoint.

Collate's valuation has grown 10x from $100M at its seed round in January 2025 to $1B in June 2026, across 2 priced rounds.

Collate valuation by funding round

Collate valuation by funding round
DateStageValuation
Jun 2026Undisclosed stage$1B
Jan 2025Seed$100M

Collate Funding History

Collate has raised a total of $125M across 2 funding rounds.

Collate's first fundraising round was a $30M seed round in January 2025. The most recent completed round was a $95M undisclosed-stage round in June 2026.

Collate funding rounds

Collate funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Jun 2026Undisclosed stageRedpoint (lead)$95M$1BRedpoint Ventures led Collate’s June 2026 financing with $95M at an approximately $1B valuation, bringing total funding to $125M. The round was positioned around scaling Collate’s AI automation for life sciences paperwork, including regulatory submissions, clinical trial documentation, and compliance filings. Earlier reporting indicates Collate had previously raised $40M across two rounds, including a $30M seed in January 2025 and a $10M Series A in July 2025, with Redpoint Ventures listed among the seed investors. Collate operates as a life sciences AI company focused on automating documentation workflows for pharmaceutical and biotech customers.
Jan 2025SeedRedpoint (lead); Conviction Embed; First Round Capital; Y Combinator$30M$100MCollate is a biotech AI startup founded and led by Surbhi Sarna, an accomplished serial entrepreneur who previously founded nVision Medical, which Boston Scientific acquired for $275 million in 2018. The company focuses on automating labor-intensive documentation processes in the life sciences industry using large language models and AI. Collate's platform streamlines paperwork for diagnostic, medical device, and drug development companies, aiming to accelerate research and development, optimize preclinical and clinical trials, enhance quality management, and reduce time to market for new drugs, diagnostics, and devices. In January 2025, Collate emerged from stealth with a $30 million seed round led by Redpoint Ventures, with participation from First Round Capital, Conviction Partners, and Y Combinator. The round valued the company at over $100 million post-money. Satish Dharmaraj of Redpoint emphasized the long-term potential of the platform, noting its low-velocity, high-contract-value sales model would create sticky, value-generating relationships with enterprise customers in life sciences. The funding will support product development and market expansion as Collate aims to automate a critical but underserved workflow across the industry.

Who has invested in Collate?

4 investors have backed Collate across its funding rounds, including Redpoint, Y Combinator, First Round Capital and Conviction Embed.

Lead investors include Redpoint.


Collate Investors

Investors in Collate by funding rounds participated
InvestorHQRoundsRoleFirst check
RedpointUnited StatesSan Francisco, CA2LeadJan 2025
Conviction EmbedIsraelTel Aviv1ParticipantJan 2025

This data is available for Pro users. Sign up to see all 4 Collate investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Collate Competitors

Collate competitors include listed companies like Arcs Co and Appier Group, and private ones like Iambic, Altana, Augury and Beamery.

Public and private companies comparable to Collate
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Arcs CoJapanJapanPublicly listed$4B$185M$1.3B0.2x
IambicUnited StatesSan Diego, CAPrivate--$600M-
AltanaUnited StatesNew York City, NYPrivate-$564M$1B-
AuguryUnited StatesNew York City, NYPrivate$100M-$1B-
BeameryUnited KingdomLondonPrivate--$1B-
Appier GroupJapanJapanPublicly listed$281M$44M$1B2.9x

Collate Public Comps

Collate is still privately-owned, but its public comps include Appier Group, Rackspace, Extreme Vision, iFLYHealth, Rezolve AI, Beijing CTJ Info Tech, Optasia, ODDITY Tech, SEEGENE and Bide Pharmatech Co.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Appier Group$281M$44M3.4x2.9x21.6x15.7x
Rackspace$2.7B$244M1.5x1.6x17.1x15.0x
Extreme Vision$44M($6M)22.8x11.6x(163.7x)-
iFLYHealth$136M($7M)7.7x6.2x(150.8x)(144172.5x)
Rezolve AI$47M($109M)23.3x4.0x(10.0x)(19.3x)
Beijing CTJ Info Tech$123M$13M5.3x4.9x51.3x34.6x
Optasia$265M$79M4.3x3.6x14.5x9.1x
ODDITY Tech$810M$131M1.5x1.8x9.6x18.3x

This data is available for Pro users. Sign up to see all Collate competitors and their valuation data.

Start Free Trial

Common questions about Collate

When was Collate founded?Collate was founded in 2025.
Where is Collate headquartered?Collate is headquartered in San Francisco, CA, United States.
Is Collate publicly listed?No, Collate is a private, VC-backed company.
What is Collate's valuation?Collate was last valued at $1B in its undisclosed-stage round in June 2026.
How much funding has Collate raised?Collate has raised $125M across 2 funding rounds.
What was Collate's last funding round?Collate's last funding round was a $95M undisclosed-stage round in June 2026, led by Redpoint.
Who are Collate's investors?Collate's investors include Redpoint, Conviction Embed, First Round Capital and Y Combinator.
Which companies are comparable to Collate?Companies comparable to Collate include Arcs Co, Iambic, Altana, Augury, Beamery and Appier Group.

See companies similar to Collate

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial